Novartis Spends 8.7 BN$ To Acquire Gene Therapy
AveXis, Inc. the US-based Nasdaq-listed clinical-stage gene therapy company has been acquired by Novartis for USD 218 per share or ...
Read moreDetails
Menu
AveXis, Inc. the US-based Nasdaq-listed clinical-stage gene therapy company has been acquired by Novartis for USD 218 per share or ...
Read moreDetails
©2024 Copyright. RVCJ Digital Media Pvt Ltd